Logos Global Management LP
Position in DNTH — Dianthus Therapeutics, Inc. /DE/
CIK 1792126
San Francisco, CA
Position in DNTH
as of Jun 30, 2026
· filed Aug 14, 2026
Position Value
$77,984,000
+$44,416,000 QoQ
Shares Held
800,000
+100.0% QoQ
Ownership
1.43%
of shares outstanding
% of Portfolio
3.36%
of 13F equity value
Holder Rank
#23
of 269 holders
Holding Since
Sep 2025
4 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in DNTH Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Logos Global Management LP holds $2,282,084,584 across 63 Biotechnology names. DNTH ranks #10 (3.4% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ERAS |
Erasca, Inc.
|
12,150,000 | $222,588,000 | |
| 2 | ABVX |
Abivax S.A.
|
1,024,000 | $136,458,240 | |
| 3 | RVMD |
Revolution Medicines, Inc.
|
700,000 | $131,096,000 | |
| 4 | IDYA |
IDEAYA Biosciences, Inc.
|
3,000,000 | $111,810,000 | |
| 5 | BNTX |
BioNTech SE
|
1,015,000 | $94,445,750 | |
| 6 | VERA |
Vera Therapeutics, Inc.
|
2,200,000 | $94,402,000 | |
| 7 | TNGX |
Tango Therapeutics, Inc.
|
2,850,000 | $89,091,000 | |
| 8 | PRAX |
Praxis Precision Medicines, Inc.
|
260,000 | $87,045,400 |
All Filings in DNTH
Export CSV
4 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $77,984,000 | 800,000 | Shares | Sole | 2026-08-14 | |
| 2026-03-31 | $33,568,000 | 400,000 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $12,981,150 | 315,000 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $7,870,000 | 200,000 | Shares | Sole | 2025-11-14 | |
| No filing history on record for this holder in this stock. | ||||||